MedTrace Logo

Efficacy and Safety of Kukoamine B Mesilate in Sepsis Patients

NCT04803955 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 424

Last updated 2024-04-10

No results posted yet for this study

Summary

Phase II study of Kukoamine B Mesilate in Sepsis Patients

Conditions

Interventions

DRUG

16mg，KB

16mg,Q8h±3min,Day1-Day7

DRUG

Placebos

16mg,Q8h±3min,Day1-Day7

Sponsors & Collaborators

  • Southwest Hospital, China

    collaborator OTHER

  • Tianjin Chasesun Pharmaceutical Co., LTD

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-15
Primary Completion
2024-05-30
Completion
2024-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04803955 on ClinicalTrials.gov